A61K31/185

TAURINE COMPOSITIONS SUITABLE FOR INHALATION
20170281546 · 2017-10-05 ·

The invention discloses spray-dried compositions for inhalation and methods for preparing such powder compositions. The compositions of the invention are produced by spray-drying taurine under conditions that (i) retain the physical and chemical stability of the composition during spray drying and upon storage, (ii) protect the powder composition from aggregation and (iii) provide particles suitable for aerosolisation.

FORMULATION FOR TREATING CHRONIC WOUNDS
20170281572 · 2017-10-05 ·

Inventive subject matter disclosed herein includes a method for treating a chronic wound, and methods for treating bacterial infections. The method for treating a chronic wound includes mechanically debriding a chronic wound, and applying a formulation to the wound for 5 to 60 seconds, the formulation including: phenolsulfonic acid—37% by weight; guaiacolsulfonic acid—24% by weight; free sulfuric acid—29% by weight; and water—10% by weight.

FORMULATION FOR TREATING CHRONIC WOUNDS
20170281572 · 2017-10-05 ·

Inventive subject matter disclosed herein includes a method for treating a chronic wound, and methods for treating bacterial infections. The method for treating a chronic wound includes mechanically debriding a chronic wound, and applying a formulation to the wound for 5 to 60 seconds, the formulation including: phenolsulfonic acid—37% by weight; guaiacolsulfonic acid—24% by weight; free sulfuric acid—29% by weight; and water—10% by weight.

FORMULATION FOR TREATING CHRONIC WOUNDS
20170281572 · 2017-10-05 ·

Inventive subject matter disclosed herein includes a method for treating a chronic wound, and methods for treating bacterial infections. The method for treating a chronic wound includes mechanically debriding a chronic wound, and applying a formulation to the wound for 5 to 60 seconds, the formulation including: phenolsulfonic acid—37% by weight; guaiacolsulfonic acid—24% by weight; free sulfuric acid—29% by weight; and water—10% by weight.

A SALT OF CEPHALOSPORIN DERIVATIVE, ITS CRYSTALLINE SOLID AND A METHOD OF MANUFACTURING THEREOF

The present invention provides an acid addition salt or a sodium salt of a compound represented by the formula (IA):

##STR00001##

or their hydrate or a stable crystalline solid thereof. The salt or the crystalline solid is extremely useful as an active ingredient for the production of a pharmaceutical product.

A SALT OF CEPHALOSPORIN DERIVATIVE, ITS CRYSTALLINE SOLID AND A METHOD OF MANUFACTURING THEREOF

The present invention provides an acid addition salt or a sodium salt of a compound represented by the formula (IA):

##STR00001##

or their hydrate or a stable crystalline solid thereof. The salt or the crystalline solid is extremely useful as an active ingredient for the production of a pharmaceutical product.

Compounds as modulators of protein kinases

The present invention provides PI3K protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of kinase mediated diseases or disorders with them.

Compounds as modulators of protein kinases

The present invention provides PI3K protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of kinase mediated diseases or disorders with them.

NEW THERAPEUTIC APPROACHES FOR TREATING PARKINSON'S DISEASE

The present invention relates to compositions and methods for the treatment of Parkinson's disease and related disorders. More specifically, the present invention relates to novel combinatorial therapies of Parkinson's disease and related disorders targeting the alpha-synuclein aggregation network. In particular, the invention relates to compounds which, alone or in combination(s), can effectively protect neuronal cells from alpha-synuclein aggregates. The invention also relates to methods of producing a drug or a drug combination for treating Parkinson's disease and to methods of treating Parkinson's disease or a related disorder.

NEW THERAPEUTIC APPROACHES FOR TREATING PARKINSON'S DISEASE

The present invention relates to compositions and methods for the treatment of Parkinson's disease and related disorders. More specifically, the present invention relates to novel combinatorial therapies of Parkinson's disease and related disorders targeting the alpha-synuclein aggregation network. In particular, the invention relates to compounds which, alone or in combination(s), can effectively protect neuronal cells from alpha-synuclein aggregates. The invention also relates to methods of producing a drug or a drug combination for treating Parkinson's disease and to methods of treating Parkinson's disease or a related disorder.